The new facility is located at its Braine-l’Alleud site and will employ 100 employees. This new facility will produce cell culture-based therapeutic proteins that are dedicated to accelerating the availability of new drugs for severe diseases with a focus on the research and clinical trial phases
This new facility is designed enable UCB to improve its biological medicines.
Chief executive Roch Doliveux said that “today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline”. He added that “with this bio pilot plant, we will more rapidly initiate clinical studies of new antibody-based therapeutics”.